The subject of this publication is the conclusion of contracts in accordance with Section 130a (8) SGB V for the following active substances / combinations of active substances in the context of a so-called open house procedure:

Clobetasol (D07AD01)

Dasatinib (L01EA02)

Dexamethasone & Gentamicin (S01CA21)

Melatonin (N05CH01)

Natriumoxybat (N01AX11, N07XX04)

Permethrin (P03AC04)

Tafluprost (S01EE05)

Telmisartan & Amlodipin (C09DB04)

Therapy allergen trees (V01AA05)

Therapy allergen grasses (V01AA02)

Therapy allergen mite (V01AA03)

Therapieallergen SCIT (V01AA02, V01AA03, V01AA05)

Trientin (A16AX12)

Providing uniform contractual terms and a uniform access procedure, all suitable and interested pharmaceutical companies or communities of pharmaceutical companies are offered the conclusion of a discount contract in accordance with Section 130a (8) SGB V for the active substances / combinations of active substances mentioned.

The earliest contract start is 01.04.2023. Based on this, the contract term is a maximum of 24 months.

Providing uniform contractual terms and a uniform access procedure, all suitable and interested pharmaceutical companies or communities of pharmaceutical companies are offered the conclusion of a discount contract in accordance with Section 130a (8) SGB V for the active substances / combinations of active substances mentioned.

The earliest contract start is 01.04.2023. Based on this, the contract term is a maximum of 24 months.